ResoTher Pharma receives a €2.5 million grant from European Innovation Council (EIC) to support a Phase 2a clinical study of their Lead Candidate RTP-026 for Myocardial Infarction

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

ResoTher-Pharma-EIC

More Like This

PR Newswire associated0

Heart Failure start-up, Acorai, secures €2.3m grant funding from the European Commission

Promising Preclinical Data Support TPC-026 as a Novel Chronic Therapy for Metabolic Disorders Including Obesity

CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership

PR Newswire associated0

Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award

PR Newswire associated0

Innorna Announces FDA Clearance of IND for IN026, Advancing mRNA-based Therapies into Chronic Metabolic Diseases

Rona Therapeutics Announces Breakthrough Data on Potential Annual Dosing RNAi Therapy RN026 Targeting Lipoprotein(a) in The National Lipid Association (NLA) Scientific Sessions 2025

Stablepharma Secures €2.5m EIC Accelerator Grant, Recognised Among Europe's Top 71 Innovators (Photo: Business Wire)

Stablepharma Secures €2.5m EIC Accelerator Grant, Recognised Among Europe's Top 71 Innovators

Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia